A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome

NCT07181837 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
12
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

MavriX Bio, LLC